This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Staiger, H. Articles by Häring, H.-U. Search for Related Content PubMed PubMed Citation Articles by Staiger, H. Articles by Häring, H.-U.

Pathomechanisms of Type 2 Diabetes Genes

Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology, and Clinical Chemistry, University Hospital Tübingen, D-72076 Tübingen, Germany

Correspondence: Address all correspondence and requests for reprints to: Prof. Hans-Ulrich Häring, Internal Medicine IV, Medical Clinic Tübingen, Otfried-Müller-Str. 10, D-72076 Tübingen, Germany. E-mail: hans-ulrich.haering{at}med.uni-tuebingen.de.

Type 2 diabetes mellitus is a complex metabolic disease that is caused by insulin resistance and β-cell dysfunction. Furthermore, type 2 diabetes has an evident genetic component and represents a polygenic disease. During the last decade, considerable progress was made in the identification of type 2 diabetes risk genes. This was crucially influenced by the development of affordable high-density single nucleotide polymorphism (SNP) arrays that prompted several successful genome-wide association scans in large case-control cohorts. Subsequent to the identification of type 2 diabetes risk SNPs, cohorts thoroughly phenotyped for prediabetic traits with elaborate in vivo methods allowed an initial characterization of the pathomechanisms of these SNPs. Although the underlying molecular mechanisms are still incompletely understood, a surprising result of these pathomechanistic investigations was that most of the risk SNPs affect β-cell function. This favors a β-cell-centric view on the genetics of type 2 diabetes. The aim of this review is to summarize the current knowledge about the type 2 diabetes risk genes and their variants’ pathomechanisms.

This article has been cited by other articles:

				P. A. Halban, M. S. German, S. E. Kahn, and G. C. Weir Current Status of Islet Cell Replacement and Regeneration Therapy J. Clin. Endocrinol. Metab., March 1, 2010; 95(3): 1034 - 1043. [Abstract] [Full Text] [PDF]

				S. B. Liggett {alpha}2A-Adrenergic Receptors in the Genetics, Pathogenesis, and Treatment of Type 2 Diabetes Science Translational Medicine, December 23, 2009; 1(12): 12ps15 - 12ps15. [Full Text] [PDF]